216 related articles for article (PubMed ID: 19247213)
1. Ras dependent paracrine secretion of osteopontin by Nf1+/- osteoblasts promote osteoclast activation in a neurofibromatosis type I murine model.
Li H; Liu Y; Zhang Q; Jing Y; Chen S; Song Z; Yan J; Li Y; Wu X; Zhang X; Zhang Y; Case J; Yu M; Ingram DA; Yang FC
Pediatr Res; 2009 Jun; 65(6):613-8. PubMed ID: 19247213
[TBL] [Abstract][Full Text] [Related]
2. Hyperactive Ras/MAPK signaling is critical for tibial nonunion fracture in neurofibromin-deficient mice.
Sharma R; Wu X; Rhodes SD; Chen S; He Y; Yuan J; Li J; Yang X; Li X; Jiang L; Kim ET; Stevenson DA; Viskochil D; Xu M; Yang FC
Hum Mol Genet; 2013 Dec; 22(23):4818-28. PubMed ID: 23863460
[TBL] [Abstract][Full Text] [Related]
3. Hyperactivation of p21ras and PI3K cooperate to alter murine and human neurofibromatosis type 1-haploinsufficient osteoclast functions.
Yang FC; Chen S; Robling AG; Yu X; Nebesio TD; Yan J; Morgan T; Li X; Yuan J; Hock J; Ingram DA; Clapp DW
J Clin Invest; 2006 Nov; 116(11):2880-91. PubMed ID: 17053831
[TBL] [Abstract][Full Text] [Related]
4. Neurofibromin and its inactivation of Ras are prerequisites for osteoblast functioning.
Yu X; Chen S; Potter OL; Murthy SM; Li J; Pulcini JM; Ohashi N; Winata T; Everett ET; Ingram D; Clapp WD; Hock JM
Bone; 2005 May; 36(5):793-802. PubMed ID: 15804420
[TBL] [Abstract][Full Text] [Related]
5. Phenotypic characterization of transgenic mice harboring Nf1+/- or Nf1-/- osteoclasts in otherwise Nf1+/+ background.
Alanne MH; Siljamäki E; Peltonen S; Väänänen K; Windle JJ; Parada LF; Määttä JA; Peltonen J
J Cell Biochem; 2012 Jun; 113(6):2136-46. PubMed ID: 22307743
[TBL] [Abstract][Full Text] [Related]
6. Hyperactivation of mTOR critically regulates abnormal osteoclastogenesis in neurofibromatosis Type 1.
Ma J; Li M; Hock J; Yu X
J Orthop Res; 2012 Jan; 30(1):144-52. PubMed ID: 21748792
[TBL] [Abstract][Full Text] [Related]
7. NF1 regulates a Ras-dependent vascular smooth muscle proliferative injury response.
Xu J; Ismat FA; Wang T; Yang J; Epstein JA
Circulation; 2007 Nov; 116(19):2148-56. PubMed ID: 17967772
[TBL] [Abstract][Full Text] [Related]
8. Recent insights into bone development, homeostasis, and repair in type 1 neurofibromatosis (NF1).
Schindeler A; Little DG
Bone; 2008 Apr; 42(4):616-22. PubMed ID: 18248783
[TBL] [Abstract][Full Text] [Related]
9. Rac1 mediates the osteoclast gains-in-function induced by haploinsufficiency of Nf1.
Yan J; Chen S; Zhang Y; Li X; Li Y; Wu X; Yuan J; Robling AG; Kapur R; Chan RJ; Yang FC
Hum Mol Genet; 2008 Apr; 17(7):936-48. PubMed ID: 18089636
[TBL] [Abstract][Full Text] [Related]
10. Hyperactive transforming growth factor-β1 signaling potentiates skeletal defects in a neurofibromatosis type 1 mouse model.
Rhodes SD; Wu X; He Y; Chen S; Yang H; Staser KW; Wang J; Zhang P; Jiang C; Yokota H; Dong R; Peng X; Yang X; Murthy S; Azhar M; Mohammad KS; Xu M; Guise TA; Yang FC
J Bone Miner Res; 2013 Dec; 28(12):2476-89. PubMed ID: 23703870
[TBL] [Abstract][Full Text] [Related]
11. MicroRNA-10b regulates tumorigenesis in neurofibromatosis type 1.
Chai G; Liu N; Ma J; Li H; Oblinger JL; Prahalad AK; Gong M; Chang LS; Wallace M; Muir D; Guha A; Phipps RJ; Hock JM; Yu X
Cancer Sci; 2010 Sep; 101(9):1997-2004. PubMed ID: 20550523
[TBL] [Abstract][Full Text] [Related]
12. Mice with GFAP-targeted loss of neurofibromin demonstrate increased axonal MET expression with aging.
Su W; Xing R; Guha A; Gutmann DH; Sherman LS
Glia; 2007 May; 55(7):723-33. PubMed ID: 17348023
[TBL] [Abstract][Full Text] [Related]
13. c-Fms signaling mediates neurofibromatosis Type-1 osteoclast gain-in-functions.
He Y; Rhodes SD; Chen S; Wu X; Yuan J; Yang X; Jiang L; Li X; Takahashi N; Xu M; Mohammad KS; Guise TA; Yang FC
PLoS One; 2012; 7(11):e46900. PubMed ID: 23144792
[TBL] [Abstract][Full Text] [Related]
14. NF1 tumor suppressor protein and mRNA in skeletal tissues of developing and adult normal mouse and NF1-deficient embryos.
Kuorilehto T; Nissinen M; Koivunen J; Benson MD; Peltonen J
J Bone Miner Res; 2004 Jun; 19(6):983-9. PubMed ID: 15125795
[TBL] [Abstract][Full Text] [Related]
15. The tumor suppressor neurofibromin confers sensitivity to apoptosis by Ras-dependent and Ras-independent pathways.
Shapira S; Barkan B; Friedman E; Kloog Y; Stein R
Cell Death Differ; 2007 May; 14(5):895-906. PubMed ID: 17096025
[TBL] [Abstract][Full Text] [Related]
16. Osteoclasts in neurofibromatosis type 1 display enhanced resorption capacity, aberrant morphology, and resistance to serum deprivation.
Heervä E; Alanne MH; Peltonen S; Kuorilehto T; Hentunen T; Väänänen K; Peltonen J
Bone; 2010 Sep; 47(3):583-90. PubMed ID: 20541045
[TBL] [Abstract][Full Text] [Related]
17. Aberrant Myeloid Differentiation Contributes to the Development of Osteoporosis in Neurofibromatosis Type 1.
Rhodes SD; Yang FC
Curr Osteoporos Rep; 2016 Feb; 14(1):10-5. PubMed ID: 26932441
[TBL] [Abstract][Full Text] [Related]
18. Modeling bone morphogenetic protein and bisphosphonate combination therapy in wild-type and Nf1 haploinsufficient mice.
Schindeler A; Ramachandran M; Godfrey C; Morse A; McDonald M; Mikulec K; Little DG
J Orthop Res; 2008 Jan; 26(1):65-74. PubMed ID: 17787010
[TBL] [Abstract][Full Text] [Related]
19. Mice lacking Nf1 in osteochondroprogenitor cells display skeletal dysplasia similar to patients with neurofibromatosis type I.
Wang W; Nyman JS; Ono K; Stevenson DA; Yang X; Elefteriou F
Hum Mol Genet; 2011 Oct; 20(20):3910-24. PubMed ID: 21757497
[TBL] [Abstract][Full Text] [Related]
20. Neurofibromin haploinsufficiency results in altered spermatogenesis in a mouse model of neurofibromatosis type 1.
Chohan H; Esfandiarei M; Arman D; Van Raamsdonk CD; van Breemen C; Friedman JM; Jett KA
PLoS One; 2018; 13(12):e0208835. PubMed ID: 30571760
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
